A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke

Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Stroke
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ACTION
  • Sponsors Biogen
  • Most Recent Events

    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 19 Feb 2016 Primary endpoint of relative change in infarct growth from baseline to day 5 assessed by MRI has not been met, according to results presented at the 41st International Stroke Conference.
    • 19 Feb 2016 Results presented at the 41st International Stroke Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top